### FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
	3235-0287						
Estimated average burden							
nours per response	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)																
1. Name and Address of Reporting Person * KEEGAN JOSEPH D				2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) 614 MCKINLEY PLACE NE				3. Date of Earliest Transaction (Month/Day/Year) 10/24/2019										Officer (give	e title below)	Othe	er (specify belo	ow)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line)  _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
	APOLIS, N													im inca oy		reporting reison		
(Cit	y)	(State)	(Zip)			7	Γable	e I - No	n-Deri	vative	Securitie	s Acqui	ired, l	Disposed	of, or Bene	ficially Owner	ed	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year	/		Date, if	Cod (Ins	Transaction de str. 8)		4. Securities Acq (A) or Disposed of (Instr. 3, 4 and 5)		of (D) Owr Tran		5. Amount of Securities Beneficially Owned Following Reported Fransaction(s)		ed [	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership	
				(Month/Day/Year)		Code		V	Amount (A) or (D)		Price	(Instr. 3 and 4		+)				
Common	mmon Stock 10/24/2019							A	4	95	A	\$ 0	1,74	8		]	D	
(Instr. 3) Pric	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	(e.g., puts, calls,           4.         5.1           Transaction of Code         De           Instr. 8)         Sec           Ac         Ac           Dis         Of           (In         (In		5. Num	rran iber tive ties	Expiration Date of (Month/Day/Year)		icially Owned		Amount ng	8. Price of Derivative Security (Instr. 5)	f 9. Number of e Derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		ve Ownershi		
	Security					(A) or Disposed of (D) (Instr. 3, 4 and 5)		Date Exercisabl		Expiration		Title			Amount or Number		Direct (or Indir (I) (Instr. 4	ect
				Code	V	(A)	(D)	Exerc	isabie	Date				of Shares				
Stock Option (right to buy)	\$ 125.05							10/2:	5/2018	3 10/2	26/2027	Comi		3,125		3,125	D	
Stock Option (right to buy)	\$ 179.84							10/24	4/2019	10/2	25/2028	Comi		1,898		1,898	D	
Stock Option (right to buy)	\$ 201.64	10/24/2019		A		2,011			(1)	10/2	24/2029	Comi		2,011	\$ 0	2,011	D	

## **Reporting Owners**

	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
KEEGAN JOSEPH D 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413	X						

### **Signatures**

/s/ Brenda S. Furlow as Attorney-in-Fact for Joseph D. Keegan pursuant to Power of Attorney previously filed	10/28/2019	
**Signature of Reporting Person	Date	

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The option vests on the earlier of the one year anniversary of the grant date (10/24/2019) or the date of Bio-Techne's 2020 annual meeting of shareholders

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.